Market Place
Sourcing Support
Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing
01 Jun 2024 //
ENDPTS
Optimi Secures Import Permit For MDMA, Psilocybin From Mind Medicine
29 May 2024 //
GLOBENEWSWIRE
Optimi, ATMA Advance MDD Trial For Group, Individual
22 May 2024 //
GLOBENEWSWIRE
Optimi Receives Analysis For GMP MDMA 40mg, 60mg Capsules
14 May 2024 //
GLOBENEWSWIRE
Optimi Health Provides Corporate Update
10 May 2024 //
GLOBENEWSWIRE
Optimi Gets Permit To Ship MDMA To Tel Aviv Psychedelic Institute
09 May 2024 //
GLOBENEWSWIRE
Optimi Health, KPU Partner On Mushroom R&D
23 Apr 2024 //
GLOBENEWSWIRE
Optimi Completes In-House MDMA API Production
15 Apr 2024 //
GLOBENEWSWIRE
Optimi Health signs Psilocybin Supply Agreement
09 Apr 2024 //
GLOBENEWSWIRE
Optimi Receives Product Results and COA for GMP Natural Psilocybin Extract
02 Apr 2024 //
GLOBENEWSWIRE
Optimi Health Confirms Presenting Sponsorship at the Conference
28 Mar 2024 //
GLOBENEWSWIRE
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 Feb 2024 //
GLOBENEWSWIRE
Optimi Health Granted Precursor Licence To Formulate MDMA
03 Jan 2024 //
GLOBENEWSWIRE
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
07 Dec 2023 //
GLOBENEWSWIRE
Optimi Health Resolves Dispute
10 Nov 2023 //
GLOBENEWSWIRE
Optimi Health Announces Third Secured for Debt Financing
02 Nov 2023 //
GLOBENEWSWIRE
Optimi Granted Amendment to Dealer`s Licence by Health Canada
07 Sep 2023 //
GLOBENEWSWIRE
Optimi Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
05 Sep 2023 //
GLOBENEWSWIRE
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
10 Aug 2023 //
GLOBENEWSWIRE
Optimi Completes Proprietary Natural Psilocybin Extraction Process
01 Aug 2023 //
GLOBENEWSWIRE
Optimi Health Announces Receipt of Purported Termination Notice
27 Jul 2023 //
GLOBENEWSWIRE
Optimi Health To Supply MDMA For Therapist Experiential Program at Nuus
15 Jun 2023 //
GLOBENEWSWIRE
Optimi Completes Harvest Of Psilocybe Cubensis For Delivery To Medical Market
17 May 2023 //
GLOBENEWSWIRE
Optimi Health Granted Natural Health Product Site Licence By Health Canada
10 May 2023 //
GLOBENEWSWIRE
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement
04 May 2023 //
GLOBENEWSWIRE
Optimi Submits PI Trial Application Combining The Use Of Proprietary Psilocybin
07 Feb 2023 //
GLOBENEWSWIRE
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
06 Feb 2023 //
GLOBENEWSWIRE
Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers
17 Jan 2023 //
GLOBENEWSWIRE
Optimi Health Announces Re-Appointments to Board of Directors
10 Jan 2023 //
GLOBENEWSWIRE
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement
11 Oct 2022 //
GLOBENEWSWIRE
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin
22 Sep 2022 //
GLOBENEWSWIRE
Optimi Health Enters Into International Collaborative Research and Supply
30 Aug 2022 //
GLOBENEWSWIRE
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
16 Aug 2022 //
GLOBENEWSWIRE
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin
10 Aug 2022 //
GLOBENEWSWIRE
Optimi Health To Launch Therapeutic Psilocybin Product
08 Aug 2022 //
GLOBENEWSWIRE
Optimi Health Finalizes Psilocybin Supply Agreement
13 Jul 2022 //
GLOBENEWSWIRE
Optimi Health Sighns Agreement With SABI Mind For Supplies Of Psilocybin, MDMA
28 Jun 2022 //
GLOBENEWSWIRE
Optimi Health Requests Approval for MDMA, Other Synthetic Psychedelics
20 Jun 2022 //
GLOBENEWSWIRE
Optimi Health Finalizes Partnership and Psilocybin Supply Agreement
08 Jun 2022 //
GLOBENEWSWIRE
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
31 May 2022 //
GLOBENEWSWIRE
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences
27 May 2022 //
GLOBENEWSWIRE
Optimi Completes First Grow of Psilocybin Mushrooms; Brings Head of Cultivation
25 May 2022 //
GLOBENEWSWIRE
Optimi Health Acquires Catalog of Psychedelic and Functional Mushroom Genetics
17 May 2022 //
GLOBENEWSWIRE
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
11 May 2022 //
GLOBENEWSWIRE
Optimi Health Applauds Health Canada`s Position on Quality & GMP for Psilocybin
09 May 2022 //
GLOBENEWSWIRE
Optimi Health Granted Amendment To Controlled Substances Dealer`s Licence
04 May 2022 //
GLOBENEWSWIRE
Optimi Health Opens GMP-Grade Licensed Psilocybin Cultivation Facility
28 Apr 2022 //
GLOBENEWSWIRE
Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Trials
18 Mar 2022 //
GLOBENEWSWIRE
Optimi Health says Investor Relations Agreement
08 Mar 2022 //
GLOBENEWSWIRE
Optimi Health Upgrades Trading to the OTCQX Best Market
01 Mar 2022 //
GLOBENEWSWIRE
Optimi Health Approved to Supply Psilocybin Under Health Canada’s SAP
16 Feb 2022 //
GLOBENEWSWIRE
Optimi Health Dealer’s License Granted by Health Canada
07 Feb 2022 //
GLOBENEWSWIRE
Optimi Health Submits Natural Psilocybin CDD for Provisional Patent
18 Jan 2022 //
GLOBENEWSWIRE
Optimi Health Appoints New Chief Executive Officer
31 Aug 2021 //
GLOBENEWSWIRE
Optimi Health Updates Launch of Online Functional Mushroom Sales
10 Aug 2021 //
GLOBENEWSWIRE
Optimi Health Updates Launch of Online Functional Mushroom Sales
10 Aug 2021 //
GLOBENEWSWIRE
Optimi Health Initiates Pathway to Nasdaq Listing
07 Jul 2021 //
GLOBENEWSWIRE
